4 results about "Matrix Metalloprotease" patented technology

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

The present invention relates to B-hydroxy and amino substituted carboxylic acide, which act as matrix metalloprotease inhibitor, particularly diastereomerically pure B-hydroxy carboxylic acid, corresponding processes for the synthesis of and pharmaceutical composition containing the compounds of the present invention. Compound of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriaasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compound.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.

The invention relates generally to cleavable polypeptides, method of producing a cleavable moiety (CM) containing polypeptide by culturing a cell under conditions that lead to expression of the polypeptide, methods of manufacturing a cleavable moiety (CM) containing polypeptide by culturing a cell comprising a nucleic acid construct that encodes the cleavable polypeptide to express the cleavable polypeptide, and recovering the cleavable polypeptide, nucleic acids encoding the cleavable polypeptides, and vectors including the nucleic acids encoding the cleavable polypeptides.